← FDA DRUG APPROVALS

FDA ANDA · ANDA090248

ALPRAZOLAM

Sponsor: STRIDES PHARMA INTL

APPLICATION
ANDA090248
TYPE
ANDA
ORIGINAL APPROVAL
2010-09-17
LATEST ACTION
2024-04-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ALPRAZOLAMDiscontinued
ALPRAZOLAM 1MG · TABLET · ORAL
ALPRAZOLAMDiscontinued
ALPRAZOLAM 0.25MG · TABLET · ORAL
ALPRAZOLAMDiscontinued
ALPRAZOLAM 2MG · TABLET · ORAL
ALPRAZOLAMDiscontinued
ALPRAZOLAM 0.5MG · TABLET · ORAL

Approval history

2024-04-11Labeling · Supplement 7 · standardAP
2024-04-11Labeling · Supplement 8 · standardAP
2024-04-11Labeling · Supplement 6 · standardAP
2019-12-31Labeling · Supplement 5 · standardAP
2010-09-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →